The goal of HIV-1 vaccine development is the reproducible elicitation of potent, broadly 41 neutralizing antibodies (bnAbs) that can protect against infection of transmitted/founder (TF) 42 viruses (Haynes and Burton, 2017) . While ~50% of HIV-infected individuals generate bnAbs 43 (Hraber et al., 2014) , bnAbs in this setting only arise after years of infection (Bonsignori et al., 44 2016; Doria-Rose et al., 2014; Liao et al., 2013) . BnAbs isolated from infected individuals have 45 one or more unusual traits, including long third complementarity determining regions 46 (CDR3s) (Yu and Guan, 2014) , autoreactivity (Kelsoe and Haynes, 2017) , large insertions and 47 deletions (Kepler et al., 2014) , and high frequencies of somatic mutations (Burton and 48 Hangartner, 2016). Somatic hypermutation of the B cell receptor (BCR) heavy and light chain 49 genes is the primary diversification method during antibody affinity maturation -the 50 evolutionary process that drives antibody development after initial BCR rearrangement and leads 51 to high affinity antigen recognition (Teng and Papavasiliou, 2007) . Not all somatic mutations 52 acquired during antibody maturation are necessary for bnAb development; rather high mutational 53 levels may reflect the length of time required to elicit bnAbs (Georgiev et al., 2014; Jardine et 54 al., 2016b) . Therefore, shorter maturation pathways to neutralization breadth involving a critical 55 subset of mutations is desirable because antibody mutation levels induced by vaccines seldom 56 reach the mutation frequencies observed in bnAbs (Easterhoff et al., 2017; Moody et al., 2011) . 57 Importantly, within this subset of critical mutations some mutations may be probable and easy to 58 elicit, while other mutations may be improbable and very challenging to induce due to biases in 59 how mutations arise during affinity maturation. 60 Somatic hypermutation occurs prior to antigen affinity-based selection during affinity 61 maturation (De Silva and Klein, 2015; Victora and Nussenzweig, 2012) . The principal enzyme 62 that mediates somatic hypermutation is activation-induced cytidine deaminase (AID) (Di Noia 63 and Neuberger, 2007) . AID preferentially targets specific nucleotide sequence motifs (referred 64 to as "AID hot spots") while targeting of other nucleotide motifs is disfavored (referred to as 65 "AID cold spots") (Betz et al., 1993; Pham et al., 2003; Yaari et al., 2013) . AID initiates DNA 66 lesions and their subsequent repair results in a bias for which bases are substituted at the targeted 67 position (Cowell and Kepler, 2000) . The consequence of this non-uniformly random mutation 68 process is that specific amino acid substitutions occur with varying frequencies prior to antigenic 69 selection. Mutations at AID hot spots can occur frequently in the absence of antigen selection 70 due to immune activation-associated AID activity (Bonsignori et al., 2016; Yeap et al., 2015) . 71 Amino acid substitutions that occur infrequently generally require strong antigenic selection to 72 arise during maturation (Brown et al., 1992; Kocks and Rajewsky, 1988) . Such rare amino acid 73 substitutions are improbable prior to selection for two reasons: 1) base mutations must occur at 74 AID cold spots and 2) due to codon mapping, multiple base substitutions must occur for a 75 specific amino acid change to take place. Within the critical subset of mutations that grant broad 76 neutralization capacity to a bnAb lineage, those key mutations that are also improbable prior to 77 selection may represent important events in bnAb maturation and are thus compelling targets for 78 selection in a vaccine setting. We recently described a rare mutation in an early ancestor of a V3-79 glycan bnAb that allowed broad neutralization of transmitted/founder viruses demonstrating in 80 one bnAb lineage that functionally important, improbable mutations can be roadblocks in HIV-1 81 bnAb development (Bonsignori et al., 2017) . However, what has remained unclear is whether 82 and to what extent such roadblocks are a general problem for bnAb elicitation. Here we describe 83 the identification of improbable mutations in three bnAb B cell lineages, determine the 84 functional relevance of these mutations for development of bnAb neutralization potency, and 85 outline a vaccine design strategy for choosing sequential Envs capable of selecting B cells with 86 BCRs with functionally important improbable mutations.
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RESULTS
88
Identification of Functional Improbable Antibody Mutations
89
To determine the role of rare mutational events in bnAb development, we developed a 90 computational program to identify improbable antibody mutations. Our program, Antigen 91 Receptor Mutation Analyzer for Detection of Low Likelihood Occurrences (ARMADiLLO) 92 simulates the somatic hypermutation process using a model of AID targeting and base 93 substitution via DNA repair (Yaari et al., 2013) and estimates the probability of any amino acid 94 substitution in an antibody based on the frequencies observed in the computational simulation 95 (Figure 1) . 96 First, we applied ARMADiLLO retrospectively to the analysis of a mutation in a bnAb 97 lineage that occurred at an AID cold spot that we have previously shown was functionally 98 important for neutralization (Bonsignori et al., 2017) . The DH270 V3-glycan bnAb lineage 99 developed a variable heavy chain (V H ) complementary determining region 2 (CDR H2) G57R 100 mutation that when analyzed with the ARMADiLLO program was predicted to occur with <1% 101 frequency prior to selection ( Figure S1 ). This mutation was functionally critical because 102 reversion back to G57 in the DH270 bnAb lineage resulted in total loss of neutralization potency 103 and breadth (Bonsignori et al., 2017 (Figures 2A and S2A) . Single amino acid reversion mutations resulted in 127 either a reduction or total loss of heterologous HIV-1 TRO.11 neutralization for each of three 128 improbable mutations, K19T, W47L and G55W demonstrating that improbable mutations in the 129 CH235 lineage were indeed critical and could confer heterologous neutralization.
130
Identification of the K19T mutation was of particular interest because the mutation was 131 observed in all but one member of the CH235 bnAb lineage and was also present in two other 132 CD4-binding site bnAbs (Scheid et al., 2011) from different individuals that shared the same VH 133 gene segment (VH1-46) as CH235 ( Figure S3A ). We performed genomic sequencing of the 134 individual from which the CH235 lineage was isolated and confirmed that K19T was a mutation 135 and was not due to allelic variation in gene segment VH1-46 ( Figure S4) . Superposition of the 136 CH235 complex into a fully-glycosylated trimer (Stewart-Jones et al., 2016) showed that the 137 K19T mutation position was in close proximity to the N197 glycan site on the Env trimer 138 ( Figures S3B and S3C) . The K19T mutation shortened the amino acid at this position thus 139 allowing for larger glycan forms at the heterogeneously glycosylated N197 position (Behrens et   140 al., 2016) providing a structural rationale for the effect of this mutation on heterologous breadth.
141
Consistent with this hypothesis, CH235 neutralization of HIV-1 JR-FL, a tier 2 heterologous 142 virus lacking the N197 glycan site, was unaffected by the T19K reversion mutation (Table S1 143 and Figure S2A ). Moreover, we introduced the K19T mutation into the CH235 UCA and 144 observed improved binding to an early autologous Env suggesting that the improbable K19T 145 mutation may have been selected for by an early autologous virus variant ( Figure S3D ).
146
We next asked what role improbable mutations played in the maturation of a second chain showed an even larger effect on reducing neutralization than heavy chain mutations (Table   155 S1 and Figure S2B ), further underscoring, along with an atypically short CDRL3 and a critical 156 CDRL1 deletion (Zhou et al., 2013) , the importance of key improbable events in the maturation Babies develop bnAbs earlier after HIV-1 infection than adults (Goo et al., 2014; 161 Muenchhoff et al., 2016) . We analyzed the glycan-V3 epitope targeting BF520.1 bnAb, isolated 162 from an HIV-1 infected infant with many fewer mutations (12 V H amino acid mutations) 163 compared to VRC01 and CH235 bnAbs (Simonich et al., 2016) . We identified an improbable 164 mutation, N52A, located in the CDR H2 of BF520.1, reverted it to germline, and expressed the 165 resultant antibody mutant (A52N). Heterologous neutralization of the A52N reversion mutant 166 against tier 2 JR-FL virus was markedly reduced relative to wildtype BF520.1 (Figure 2C) Bonsignori et al., 2011; Gorman et al., 2016; Zhou et al., 2013) . Compared to Env- (Williams et al., 2015) , 183 the broadest and most potent HIV-1 bnAbs had the highest numbers of improbable mutations 184 ( Figure 3B ). This result may follow directly from the observations that bnAbs tend to be highly 185 mutated ( Figure S6A ) (Burton and Hangartner, 2016) , and the number of improbable mutations 186 an antibody possesses is correlated with its mutation frequency ( Figure S6B ) (Sheng et al., 187 2017). However, it is not known why most bnAbs are highly mutated. Recent work has shown 188 that not all mutations in bnAbs are essential for neutralization activity (Jardine et al., 2016b) . 189 One hypothesis is that high mutation frequency is due to the extended number of rounds of 190 somatic hypermutation required for a lineage to acquire a specific subset of mutations (Klein et 191 al., 2013 given their high mutation frequency (Table S3) . This observation, along with our experimental (Dosenovic et al., 2015; Escolano et al., 2016; Jardine et al., 2016a; Jardine et al., 225 2015; McGuire et al., 2016; Sok et al., 2016; Williams et al., 2017; Zhang et al., 2016) McGuire et al., 2013; Steichen et al., 2016; Zhang et al., 2016) . Once UCAs are engaged, 245 a vaccine must elicit mutations that keep antibody maturation on a pathway towards 246 heterologous breadth. Immunization studies with fully germline-reverted bnAb UCA knock-in 247 mice have so far failed to demonstrate the acquisition of the specific mutations that lead to full 248 bnAb neutralization capacity (Briney et al., 2016; Tian et al., 2016) suggesting that the pathways 249 that lead to breadth are blocked and not circumvented with the current generation of 250 immunogens. We propose here that one significant barrier could be the acquisition of important 251 mutations that are highly improbable and thus infrequent prior to selection in the germinal 252 center.
253
If a mutation occurs prior to selection with less than 2% probability, the cutoff we use 254 here to define an improbable mutation, its expected frequency in a germinal center would be less 255 than 1 in 50 clonally related B cells. Estimates of the number of clonally related B cells range 256 from 10-100 B cells per germinal center (Jacob et al., 1991; Tas et al., 2016) Biacore S200 instrument and data analysis was performed with the S200 BIAevaluation software 338 (Biacore/GE Healthcare) as previously described (Alam et al., 2013; Dennison et al., 2011 Cowell, L.G., and Kepler, T.B. (2000) . The nucleotide-replacement spectrum under somatic hypermutation exhibits 375 microsequence dependence that is strand-symmetric and distinct from that under germline mutation. J Immunol 164, 376 1971 Immunol 164, 376 -1976 De Silva, N.S., and Klein, U. (2015). Dynamics of B cells in germinal centres. Nat Rev Immunol 15, 137-148. 378 deCamp, A., Hraber, P., Bailer, R.T., Seaman, M.S., Ochsenbauer, C., Kappes, J., Gottardo, R., Edlefsen, P., Self, 379 S., Tang, H., et al. (2014) . 
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We would like to thank Bette Korber for many helpful discussions. We thank Figure S1 . ARMADiLLO output for DH270 heavy chain shows G57R mutation is improbable ARMADiLLO output for the DH270 heavy chain. The first three rows of each block corresponds to the DH270 UCA sequence and the following four rows correspond to the matured DH270 sequenced. The first row is the amino acid sequence for the DH270 UCA. The second row is the amino acid numbering (consecutively numbered starting at 1 for the first residue) for the DH270 UCA. The third row is the nucleotide sequence with each codon falling under the amino acid designated in row 1. The mutability score calculated with the S5F model is shown below the base in each box in this row. Each box is highlighted at AID hot spots (red; mutability score>2) and cold spots (blue; mutability score <0.3). Row 8 is the estimated probability of the amino acid observed in the matured sequence (see methods for how this is calculated). The formatting pattern of rows 1-3 is repeated for the matured DH270 in rows 4-7. Amino acid substitutions are highlighted in yellow in row 4. Nucleotide mutations are shown in dark red text. Nucleotide mutations that are the result of mutations at AID cold spots are shown with an arrow below. T  F  T   16  17  18  19  20  21  22  23  24  25  26  27  28  29 G  Y  T  F  T   16  17  18  19  20  21  22  23  24  25  26  27  28  29 C. Figure S3 . K19T mutation is conserved across all VH1-46 derived bnAb lineages and T19 position is proximal to N197 glycan site A) Amino acid multiple sequence alignment of the heavy chains of the three known VH1-46 gene segmentderived CD4 binding site bnAbs: 8ANC131, 1B2530, and the multiple member CH235 lineage aligned to the CH235 UCA. The K19T mutation (red) is observed in all three lineages suggesting convergence of this mutation in three distinct individuals. Dots denote an amino acid match with the CH235 UCA in that position. B) The T19 position (magenta) in the CH235/gp120 complex structure (PDB: 5F9W) is outside of the CH235 (heavy chain, blue; light chain, gray) binding site. The complex structure was determined with monomeric gp120 (green) and only minimal glycosylation (not shown) was resolved. C) Superposition of the CH235 complex onto a fully glycosylated SOSIP trimer (5FYL) revealed that T19 (magenta) is in close proximity (7Å) to the N197 glycan base (red) resolved in the trimer structure (green ...............T...Q.......N..V...........QL..W.D..W.R.N...N....I..  CH236  .........A..R.....TI..R.......T..I.........R..L..M.D..R.R.D...........  CH239  ...........R......T..........NNF.V............C..W.D..V.RIN...........  CH240 . D. Figure S4 . Genomic sequencing of the VH1-46 gene in the CH505 subject detected no allelic variation in the K19 codon confirming K19T was a mutation A) Sequence logo plot of VH1-46 reads from genomic sequencing of the CH505 subject. No polymorphisms due to allelic variation were detected in the K19 codon (red box). Ambiguous bases in the primer region are denoted in gray. B) Consensus of translated VH1-46 reads from the CH505 subject showed no variation in amino acid sequence from the reference allele of IGHV1-46*01 confirming that K19T was a mutation and not due to an allelic variant.
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A. Figure S5 . Representative bnAb sequences colored by mutation probability A) Heavy chain sequences for a representative set of bnAbs are highlighted by their mutation probability as estimated by ARMADiLLO. Mutations that are expected to occur frequently in the absence of selection (high probability mutations) are colored in shades of green (see legend). Mutations that are expected to occur rarely in the absence of selection (improbable mutations) are colored in shades of red (see legend). Amino acids residing in CDRs are denoted with a dark blue line above them. UCA inference was performed with only the observed bnAb sequence as input and as such there may be substantial uncertainty in mutation calls within the CDR3s. Fig. S5 (cont.) B. | | | | Fig. S5 (cont.) B. Figure S5 (cont). Representative bnAb sequences colored by mutation probability B) Kappa chain sequences for a representative set of bnAbs are highlighted by their mutation probability as estimated by ARMADiLLO. Mutations that are expected to occur frequently in the absence of selection (high probability mutations) are colored in shades of green (see legend). Mutations that are expected to occur rarely in the absence of selection (improbable mutations) are colored in shades of red (see legend). Amino acids residing in CDRs are denoted with a dark blue line above them. UCA inference was performed with only the observed bnAb sequence as input and as such there may be substantial uncertainty in mutation calls within the CDR3s. 
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C. Figure S6 . BnAbs have high mutation frequencies and mutation frequency is correlated with improbable mutations A) Histograms for the distributions of number of improbable mutations (A) and mutation frequency (B) from antibody heavy chain sequences from three groups: "RV144-induced" antibodies were isolated from RV144 vaccinated subjects by antigenically sorting with RV144 immunogens (red shaded area); "Uninfected" antibodies correspond to duplicated NGS reads from IgG antibodies isolated from PBMC samples from 8 HIV-uninfected individuals (blue shaded area; see methods for details on sampling); a representative set of published bnAb antibody sequences are shown labeled above dotted lines that correspond to their mutation frequency (defined as total number of amino acid mutations in non-CDRH3 VDJ sequence divided by non-CDRH3 VDJ sequence length). Scatterplots of B) number of improbable mutations versus amino acid mutation frequency for 7588 NGS reads from uninfected IgG antibodies from PBMC samples from 8 HIVuninfected individuals and C) number of improbable mutations versus number of probable mutations (≥2% Because AID targets hot spots according to their underlying sequence motifs, the probability of mutations is sequence context dependent, making an analytical computation of the probability of a mutation in the absence of selection all but intractable. Instead, we take a numerical approach via simulation. Here, we estimate the probability of an amino acid substitution by simulating the somatic hypermutation (SHM) process and calculating the observed frequency of that substitution in the simulated sequences. The simulation proceeds as follows. Given a matured antibody nucleotide sequence, we first infer its unmutated common ancestor (UCA) sequence (Kepler, 2013; Kepler et al., 2014) . Next, the matured antibody nucleotide sequence is aligned to the UCA nucleotide sequence and the number of sites mutated, t, is computed. Starting with the UCA sequence, 1) the mutability score of all consecutive sequence pentamers is computed according to the S5F mutability model (Yaari et al., 2013) .
2) The mutability scores for each base position in the sequence are converted into the probability distribution, !, by:
where $ " is the mutability score at position ( and ) is the length of the sequence. 3) A base position, b, is drawn randomly according to !. 4) The nucleotide n, at b, is substituted according to the S5F substitution model (Yaari et al., 2013) , resulting in sequence * + where j is the number of mutations accrued during the simulation. The procedure then iterates over steps 1-4 until j=t. This results in a simulated sequence, * , , that has acquired the same number of nucleotide mutations as observed in the matured antibody sequence of interest. If at any iteration during the simulation a mutation results in a stop codon, that sequence is discarded and the process restarts from the UCA sequence. This simulation procedure is then repeated to generate 100,000 simulated matured sequences. These nucleotide sequences are then translated to amino acid sequences.
Estimating the probability of an amino acid substitution
The estimate of the probability of any amino acid substitution -®Y at site i given the number of mutations t observed in the matured sequence of interest is then calculated as the amino acid frequency observed at site i in the simulated sequences according to:
P(0 " 1→3 |-$5, 7) = 1 : 1(0 "+ = ;) < +&= where 0 " is the amino acid at site i which has the amino acid -in the UCA sequence mutating to amino acid Y in the matured sequence of interest, UCA is the UCA sequence, N is the number
[2]
of simulated sequences, 1 is an indicator function for observing amino acid Y at site i in the jth simulated sequence. This estimate is for an amino acid substitution in the absence of selection and we use this probability as a gauge of how likely it is that a B cell would arise to have this mutation prior to antigenic selection. Amino acid substitutions that are the result of mutations that occur in AID hot spots will have high probabilities, occur frequently and a subset of the reservoir of B cell clonal members would likely have these mutations present prior to antigenic selection. Amino substitutions that are the result of cold spot mutations or require multiple base substitutions will be much less frequent and could represent significant hurdles to lineage development and these substitutions may require strong antigenic selection to be acquired during B cell maturation.
Improbable mutations
The probability of a specific amino substitution at any given position is the product of two components. The first component is due to the bias of the AID enzyme in targeting that specific base position and the DNA repair mechanisms preference for substituting to an alternative base. Practically speaking, substitutions that require mutations at AID cold spots and/or result in disfavored base substitutions by DNA repair mechanisms are infrequent and thus improbable. The second component is the number and length of available paths through codon space to go from an amino acid encoded by the codon in the UCA to that of the codon for the substituted amino acid in the matured sequence. To illustrate this, we turn to a practical example: the TAT codon which encodes the amino acid, Tyr. From the TAT codon, 5 amino acids are achievable by a single nucleotide base substitution (C,D,F,H,N,S), 12 amino acids by two base substitutions (A,E,G,I,K,L,P,Q,R,T,V,W) and 1 amino acid (M) by three base substitutions. Without considering the bias of AID, the Y->M mutation starting from the TAT codon is inherently unlikely to occur because it requires three independent mutational events to occur within the same codon. By simulating the SHM process, ARMADiLLO captures the interplay of these two components and is able to estimate the probability of any amino acid substitution prior to selection by taking both components into account.
For this study, we have selected a cutoff of less than 2% probability to classify mutations as "improbable". We chose this cutoff to reflect a frequency in which the expected number of mutations in a B cell clone in a single germinal center would be less than or equal to 1. In order to calculate the expected number of mutations, we used estimates of the number of clonally related B cells in a germinal center. The range of these estimates is ~10-100 clonally related B cells for immunizations in mice with various protein antigens (Jacob et al., 1991; Tas et al., 2016) . Thus, for a mutation that has 2% probability, the expected number of B cells with this mutation in a germinal center is 1 in 50, reflective of one mutation per clone per germinal center. To demonstrate the effects of different choices of cutoffs, we applied additional cutoffs of 1%, 0.1% and 0.01% when calculating the estimated numbers of improbable mutations in a representative set of bnAbs and these additional data are included in an Excel spreadsheet in the supplementary materials.
Calculating the expected number of improbable mutations
The number of improbable amino acid mutations, M, in an antibody sequence at a given probability cutoff can be estimated by applying [2] and enumerating over the entire amino acid sequence. For example, CH235.12 is estimated to have M=16 improbable mutations in its heavy chain when improbable mutations are defined as amino acid substitutions with <2% estimated probability. We estimate the probability of getting M improbable mutations or greater at a given amino acid mutation frequency, u, from the empirical distribution of the number of improbable mutations observed in sequences simulated to acquire T amino acid mutations, where T=u*L and L is the length of the sequence. To calculate the empirical distribution of improbable mutations for each antibody sequence of interest, we first randomly draw 1000 sequences from an antibody sequence dataset generated from NGS sequencing of 8 HIV-1 negative individuals and infer the UCA of each sequence (Kepler, 2013; Kepler et al., 2014) . From these randomly sampled UCAs, we then simulate the SHM process using the same simulation procedure as detailed above and stop the simulation when each sequence acquires T amino acid mutations. This results in a set of 1000 simulated sequences each with an amino acid mutation frequency of u. The probability of observing M or greater improbable mutations in the absence of selection is then:
where N is the number of simulations (here N=1000), 0 + is the number of improbable mutations in the jth simulated sequence (calculated from [2] over all amino acid positions in the sequence) and 1 is an indicator function. Here we exclude the CDR3 sequence from our calculations of both M and u as the inference of the UCA has widely varying levels of uncertainty in the CDR3 region depending on the input matured sequence.
Standard methods for determining selection at an amino acid site typically rely on the measure w which is the ratio of non-synonymous mutations to synonymous mutations at that position in a multiple sequence alignment of related gene sequences. Here, we avoid this measure of selection for two reasons. In many instances in this study we have only two sequences to compare, the UCA and the matured sequence. This does not provide the number of observations needed for w to reliably indicate selection. In some case, where we do have multiple clonal members to align, the number of mutational events at a site is also not sufficiently large enough for w to be reliable. Secondly, w is calculated under the assumption that non-synonymous mutations are of neutral fitness advantage. Clearly, due to the sequence dependence of AID targeting this assumption is violated in B cell evolution. Instead, we employ the heuristic that amino acid mutations that are estimated to be improbable yet occur frequently within a clone are likely to have been selected for. While indicative of selection, this too can be misleading if mutations occur early in a lineage, are neutral and generate a cold spot or colder spot, thus making it less likely for the position to mutate again. Thus, it is apparent that much work remains on developing rigorous methods for measuring selection in B cell evolution. Our approach here is to treat improbable amino acid mutations as candidates for [3] selection and to ultimately confirm the fitness advantage conferred by such mutations through experimentally testing their effect on virus neutralization and antigen binding.
Antibody sequences from HIV-1 negative subjects
We utilized a previously described next generation sequencing dataset generated from 8 HIV-1 negative individuals prior to vaccination (Williams et al., 2015) . Briefly, to mitigate error introduced during the PCR amplification, we split the RNA sample into two samples, A and B, and performed PCR amplification on each, independently. Only VDJ sequences that duplicated identically in A and B were then retained. This approach allowed us to be highly confident that nucleotide variations from germline gene segments that occurred in the NGS reads were mutations and not error introduced during PCR. We refer to this dataset as "uninfected".
